---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-22-000194"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:35:29.110238+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly Q2 EPS $1.05 ($1.25 non-GAAP); revenue down 4% to $6.49B; key growth products up 20%

## Summary
- Revenue $6,488M (-4% YoY; -1% constant currency); core revenue up 6% excluding Alimta, Cialis rights sale, COVID antibodies.
- Reported EPS $1.05 (-31%); non-GAAP EPS $1.25 (-32%); both include $0.46 acquired IPR&D charges.
- Key growth products (Trulicity, Verzenio, Jardiance etc.) grew 20% to 67% of revenue (ex COVID antibodies).
- 2022 guidance: reported EPS $6.96-$7.11, non-GAAP $7.90-$8.05; revenue guidance unchanged.
- FDA accepted donanemab (Alzheimer's) and pirtobrutinib (MCL) with Priority Review; Mounjaro approved for T2D; Olumiant for alopecia areata.

## SEC filing metadata
- accession: 0000059478-22-000194
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947822000194/0000059478-22-000194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947822000194/lly-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-22-000194
- JSON: https://secwatch.observer/filing/0000059478-22-000194.json
- Plain text: https://secwatch.observer/filing/0000059478-22-000194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.